On April 12, 2022 Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, reported that it has partnered with BioTools, Inc to clearly define PTB’s higher order molecular structure (HOS) (Press release, Nascent Biotech, APR 12, 2022, View Source [SID1234612059]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool’s groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification.
PTB is a natural human IgG1 antibody isolated from a patient with cervical carcinoma. It is a protein molecule comprised of multiple amino acid units linked together into a chain which can then fold into various configurations. Both the folding ("secondary structure") and the more extensive, 3-dimensional results ("tertiary structure") have dramatic impact on the molecule’s pharmaceutical effectiveness.
"BioTools is known worldwide for their knowledge and expertise in the field of Raman, ROA, and biologic FTIR. We are very pleased to have had an opportunity to work with their scientists to deliver this refined capability for our monoclonal antibody (mAb) development platform."-Sean Carrick, CEO, Nascent Biotech Inc.
"Nascent’s mAb PTB is an ideal match for our instrumentation as well as for our vision of expanding Raman/ROA+FTIR to more widespread, routine use in BioPharma research labs. This suite of techniques, coupled with the accompanying BioTools’ databases and software, have powerful application to the characterization of higher order structures for many therapeutics."-BioTools, President & Co-Founder, Dr. Rina Dukor